Normalization of serum B‐cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment

Summary Serum B‐cell maturation antigen (sBCMA) is a novel biomarker for B‐cell malignancies. A normal reference range (

Saved in:
Bibliographic Details
Published in:British journal of haematology 2021-01, Vol.192 (2), p.272-280
Main Authors: Jew, Scott, Chang, Tiffany, Bujarski, Sean, Soof, Camilia, Chen, Haiming, Safaie, Tahmineh, Li, Mingjie, Sanchez, Eric, Wang, Cathy, Spektor, Tanya M., Emamy‐Sadr, Marsiye, Swift, Regina, Rahbari, Ashkon, Patil, Saurabh, Souther, Eric, Berenson, James R.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antigens
B-Cell Maturation Antigen - blood
Female
Hematology
Humans
Male
Middle Aged
Multiple myeloma
Multiple Myeloma - blood
Multiple Myeloma - diagnosis
Multiple Myeloma - therapy
overall survival
Prognosis
Remission
serum B‐cell maturation antigen
Survival Analysis
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Serum B‐cell maturation antigen (sBCMA) is a novel biomarker for B‐cell malignancies. A normal reference range (
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.16752